We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin (AMRN) Misses Earnings & Beats Revenues in Q4
Read MoreHide Full Article
Amarin Corporation PLC (AMRN - Free Report) is a pharmaceutical company focused on developing innovating treatments for improving cardiovascular health. The company’s sole marketed drug, Vascepa, is approved as an adjunct to diet to reduce triglyceride levels in severe hypertriglyceridemia patients.
Amarin’s earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average negative earnings surprise of 12.92%, missing estimates in two quarters, beating the same once and meeting once.
Currently, Amarin’s has a Zacks Rank #3 (Hold) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Amarin reported an adjusted loss of 9 cents (excluding stock based compensation) per American depositary share which was wider than the Zacks Consensus Estimate of loss of 5 cents.
Revenues Miss: Amarin posted revenues of $77.3 million, missing the consensus estimate of $74.45 million. However, it was up 44.1% year over year.
Key Stats: Selling, general and administrative expenses were up 123.6% at $79.7 million while research & development expenses decreased 0.3% to $11.9 million. Normalized prescriptions for Vascepa increased approximately 32% year-over-year. The company is on track to file the label expansion regulatory application for Vascepa to include cardiovascular data from REDUCE-IT study by March end.
2019 Guidance: Amarin maintained its guidance provided in preliminary results release. The company expects Vacepa sales to reach $350 million in 2019 which excludes any impact from potential label expansion.
Share Price Impact: Shares were up almost 3.7% in pre-market trading.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Image: Bigstock
Amarin (AMRN) Misses Earnings & Beats Revenues in Q4
Amarin Corporation PLC (AMRN - Free Report) is a pharmaceutical company focused on developing innovating treatments for improving cardiovascular health. The company’s sole marketed drug, Vascepa, is approved as an adjunct to diet to reduce triglyceride levels in severe hypertriglyceridemia patients.
Amarin’s earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average negative earnings surprise of 12.92%, missing estimates in two quarters, beating the same once and meeting once.
Currently, Amarin’s has a Zacks Rank #3 (Hold) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Amarin reported an adjusted loss of 9 cents (excluding stock based compensation) per American depositary share which was wider than the Zacks Consensus Estimate of loss of 5 cents.
Revenues Miss: Amarin posted revenues of $77.3 million, missing the consensus estimate of $74.45 million. However, it was up 44.1% year over year.
Key Stats: Selling, general and administrative expenses were up 123.6% at $79.7 million while research & development expenses decreased 0.3% to $11.9 million. Normalized prescriptions for Vascepa increased approximately 32% year-over-year. The company is on track to file the label expansion regulatory application for Vascepa to include cardiovascular data from REDUCE-IT study by March end.
2019 Guidance: Amarin maintained its guidance provided in preliminary results release. The company expects Vacepa sales to reach $350 million in 2019 which excludes any impact from potential label expansion.
Share Price Impact: Shares were up almost 3.7% in pre-market trading.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>